Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Paul Markovitz

Psychiatry Fresno, CA Medical Doctor

NPI 1083739767 CMS profile 48872

7409 N Cedar Avenue, Suite 101, Fresno, CA 93720

Open in the dashboard

General payments

$61,930

220 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Paul Markovitz of Fresno, CA is reported in the CMS Open Payments database as having received $61,930 across 220 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $77 4
2021 General $546 39
2020 General $4,185 43
2019 General $57,123 134

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Markovitz
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Paul Markovitz were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Paul Markovitz Psychiatry median Middle half National median
2019 $57,123 $184 $59–$605 $163
2020 $4,185 $119 $36–$372 $114
2021 $546 $143 $43–$576 $132
2022 $77 $153 $50–$590 $149
2023 $0 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Neurocrine Biosciences, Inc. $60,359 101 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $462 56 payments
  3. Lundbeck LLC $315 19 payments
  4. AbbVie, Inc. $197 10 payments
  5. Allergan Inc. $186 14 payments
  6. Sunovion Pharmaceuticals Inc. $114 2 payments
  7. Jazz Pharmaceuticals Inc. $104 6 payments
  8. Eisai Inc. $96 6 payments
  9. Avanir Pharmaceuticals, Inc. $69 4 payments
  10. Vanda Pharmaceuticals Inc. $29 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $50,700 26 payments
  2. Travel and Lodging $7,863 41 payments
  3. Food and Beverage $3,366 152 payments
  4. Education $1 1 payment
Products named General payments · program years 2019–2022
  1. INGREZZA $60,359 101 payments
  2. TRINTELLIX Neuroscience $310 31 payments
  3. BRINTELLIX $219 12 payments
  4. VRAYLAR Neuroscience $186 14 payments
  5. VRAYLAR Neuroscience $155 8 payments
  6. Trintellix Central Nervous System (CNS) $148 24 payments
  7. LATUDA $114 2 payments
  8. Dayvigo $96 6 payments
  9. REXULTI $96 7 payments
  10. NUEDEXTA $69 4 payments
  11. Other $207 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

220 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record